ArticleeLife2020
Modulation of dopamine D
Open access · goldAbstract read
In one paragraph
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Review
- Single-molecule localization microscopy as a tool to quantify di/oligomerization of receptor tyrosine kinases and G protein-coupled receptors.Molecular pharmacology · 2025Review
- Dopamine D1 receptor agonist alleviates post-weaning isolation-induced neuroinflammation and depression-like behaviors in female mice.Behavioral and brain functions : BBF · 2025Article
- The Interaction of Histamine HPharmaceuticals (Basel, Switzerland) · 2024Review
- Computational Assessment of the Phytochemicals of Panax ginseng C.A. Meyer Against Dopamine Receptor D1 for Early Huntington's Disease Prophylactics.Cell biochemistry and biophysics · 2024Article
- Histaminergic System Activity in the Central Nervous System: The Role in Neurodevelopmental and Neurodegenerative Disorders.International journal of molecular sciences · 2024Review
- Histamine HBiomolecules · 2024Review
- Neurodegenerative Diseases: New Hopes and Perspectives.Current molecular medicine · 2024Review
- Discovery of a Tritiated Radioligand with High Affinity and Selectivity for the Histamine HACS medicinal chemistry letters · 2023Article
- IGF/mTORC1/S6 Signaling Is Potentiated and Prolonged by Acute Loading of Subtoxicological Manganese Ion.Biomolecules · 2023Article
- The histamine H3 receptor modulates dopamine D2 receptor-dependent signaling pathways and mouse behaviors.The Journal of biological chemistry · 2023Article
- Role of Dopamine in the Heart in Health and Disease.International journal of molecular sciences · 2023Review
- G Protein-Dependent Activation of the PKA-Erk1/2 Pathway by the Striatal Dopamine D1/D3 Receptor Heteromer Involves Beta-Arrestin and the Tyrosine Phosphatase Shp-2.Biomolecules · 2023Article
- Activation of 2-oxoglutarate receptor 1 (OXGR1) by α-ketoglutarate (αKG) does not detectably stimulate Pendrin-mediated anion exchange in Xenopus oocytes.Physiological reports · 2022Article
- G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs).Pharmacology & therapeutics · 2022Review
- Revisiting Preclinical Observations of Several Histamine H3 Receptor Antagonists/Inverse Agonists in Cognitive Impairment, Anxiety, Depression, and Sleep-Wake Cycle Disorder.Frontiers in pharmacology · 2022Review
- The Novel Alpha-2 Adrenoceptor Inhibitor Beditin Reduces Cytotoxicity and Huntingtin Aggregates in Cell Models of Huntington's Disease.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Regulation of membrane NMDA receptors by dynamics and protein interactions.The Journal of cell biology · 2021Review
- Article
- Immunomodulatory Effects of Dopamine in Inflammatory Diseases.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 4 countries.
David Moreno-Delgado *Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.
Mar Puigdellívol *Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, Spain.ORCID 0000-0002-9955-3558
Estefanía MorenoDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.
Mar Rodríguez-RuizDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.
Joaquín BottaDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.ORCID 0000-0001-6450-1267
Paola GasperiniSchool of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, United Kingdom.
Anna ChiarloneCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, Spain.
Lesley A HowellSchool of Biological and Chemical Sciences, Queen Mary University of London, London, United Kingdom.
Marco ScarselliDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Vicent CasadóDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.
Antoni CortésDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.
Sergi FerréNational Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, United States.
Manuel GuzmánCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, Spain.
Carmen LluísDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.
Jordi AlberchCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, Spain.ORCID 0000-0002-8684-2721
Enric I CanelaDepartment of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.ORCID 0000-0003-4992-7440
Silvia Ginés *Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid, Spain.ORCID 0000-0002-9479-8185
Peter J McCormick *Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, Barcelona, Spain.ORCID 0000-0002-2225-5181
Biomedical Research Networking Center on Neurodegenerative Diseases · ESUniversity of East Anglia · GBUniversidad Complutense de Madrid · ESNational Institutes of Health · USQueen Mary University of London · GBUniversity of Pisa · IT
Funding
BBSRC BB/N504282/3BBSRC CASE MCCORMICK_U15BBFundació la Marató de TV3 20140610Jerome Lejeune Foundation FJL-01/01/2013Jerome LeJeune Foundation FJL-01/01/2013Medical Research Council MR/S022465/1Ministerio de Economia y Competitividad RTI2018-094374-B-I00Ministerio de Economia y Competitividad RTI2018-095311-B-I00Ministerio de Economia y Competitividad SAF2017-88076-RMRC MR/S022465/1RSC Grant Project RG140118
Abstract
Early Huntington's disease (HD) include over-activation of dopamine D
Indexed as
Receptors, Dopamine D1Receptors, Histamine H3AnimalsCells, CulturedDrug Delivery SystemsFemaleGene Knock-In TechniquesHEK293 CellsHumansHuntington DiseaseMaleMiceMice, TransgenicPiperidinesRecombinant Fusion ProteinsVisual CortexPiperidinesReceptors, Dopamine D1Receptors, Histamine H3Recombinant Fusion Proteinsthioperamidedopamineg-protein coupled receptorshistaminehuntington's diseasemouseneuroscience
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.